Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127026181 | 12702618 | 1 | I | 20160109 | 20160822 | 20160831 | 20160831 | EXP | CN-SA-2016SA156964 | AVENTIS | 60.00 | YR | A | M | Y | 68.00000 | KG | 20160831 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127026181 | 12702618 | 1 | PS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | Y | 5A872 | 20839 | 75 | MG | TABLET | QD | |||||
| 127026181 | 12702618 | 2 | SS | DANSHEN LIGUSTRAZINE | HERBALS | 1 | Intravenous drip | Y | 20150923 | 0 | 10 | ML | INJECTION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127026181 | 12702618 | 1 | Coagulopathy |
| 127026181 | 12702618 | 2 | Cardiovascular insufficiency |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127026181 | 12702618 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127026181 | 12702618 | Pruritus | |
| 127026181 | 12702618 | Rash | |
| 127026181 | 12702618 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127026181 | 12702618 | 1 | 20160105 | 20160109 | 0 | |
| 127026181 | 12702618 | 2 | 20160105 | 20160109 | 0 |